Literature DB >> 15459143

Sputum versus bronchoscopy for diagnosis of Pseudomonas aeruginosa biofilms in cystic fibrosis.

S D Aaron1, D Kottachchi, W J Ferris, K L Vandemheen, M L St Denis, A Plouffe, S P Doucette, R Saginur, F T Chan, K Ramotar.   

Abstract

The present authors hypothesised that bronchoscopy with protected specimen brush may sample biofilm-forming bacteria adherent to the airway wall, whereas traditional sputum collection may not. Pseudomonas aeruginosa obtained from sputum, bronchoalveolar lavage and protected brush, taken from the right upper lung bronchus of 12 adult patients with cystic fibrosis, were compared. Retrieved bacteria were genotyped, and grown in planktonic cultures and as biofilms, and susceptibilities to individual antibiotics and to antibiotic combinations were determined. Bacterial cultures obtained using bronchoscopy did not yield any new strains of bacteria that were not also found in sputum. A total of 10 patients (83%) had a single strain of P. aeruginosa found using sputum, bronchoalveolar lavage and protected brush techniques, and two patients (17%) had two strains recovered in sputum, but only one strain was recovered using bronchoscopic techniques. Susceptibility to single antibiotics and to antibiotic combinations were not different between planktonically or biofilm-grown bacteria derived from sputum, as compared to those obtained by bronchoalveolar lavage and protected brush. In conclusion, sputum collection provides as much information as bronchoscopy for characterising the genotype and antibiotic susceptibility of chronic Pseudomonas aeruginosa infection in patients with stable cystic fibrosis.

Entities:  

Mesh:

Year:  2004        PMID: 15459143     DOI: 10.1183/09031936.04.00049104

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  19 in total

1.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

Review 2.  Effect of treatments on the progression of COPD: report of a workshop held in Leuven, 11-12 March 2004.

Authors:  M Decramer; R Gosselink; P Bartsch; C-G Löfdahl; W Vincken; R Dekhuijzen; J Vestbo; R Pauwels; R Naeije; T Troosters
Journal:  Thorax       Date:  2005-04       Impact factor: 9.139

3.  Correlation between sputum and bronchoalveolar lavage fluid cultures.

Authors:  Grégory Dubourg; Cédric Abat; Jean-Marc Rolain; Didier Raoult
Journal:  J Clin Microbiol       Date:  2014-12-24       Impact factor: 5.948

4.  Persistency of Pseudomonas aeruginosa in sputum cultures and clinical outcomes in adult patients with cystic fibrosis.

Authors:  A Burkett; K L Vandemheen; T Giesbrecht-Lewis; K Ramotar; W Ferris; F Chan; S Doucette; D Fergusson; S D Aaron
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-11-23       Impact factor: 3.267

Review 5.  Is bronchoscopy an obsolete tool in cystic fibrosis? The role of bronchoscopy in cystic fibrosis and its clinical use.

Authors:  Lisa Paul
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

6.  Comparison of methods to test antibiotic combinations against heterogeneous populations of multiresistant Pseudomonas aeruginosa from patients with acute infective exacerbations in cystic fibrosis.

Authors:  Juliet E Foweraker; Christian R Laughton; Derek F Brown; Diana Bilton
Journal:  Antimicrob Agents Chemother       Date:  2009-08-24       Impact factor: 5.191

7.  The presence of quorum-sensing genes in Pseudomonas isolates infecting cystic fibrosis and non-cystic fibrosis patients.

Authors:  Leandro Reus Rodrigues Perez; Alice Beatriz Mombach Pinheiro Machado; Afonso Luís Barth
Journal:  Curr Microbiol       Date:  2013-01-03       Impact factor: 2.188

Review 8.  Endpoints for clinical trials in young children with cystic fibrosis.

Authors:  Stephanie D Davis; Alan S Brody; Mary J Emond; Lyndia C Brumback; Margaret Rosenfeld
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

Review 9.  Sputum biomarkers of inflammation in cystic fibrosis lung disease.

Authors:  Scott D Sagel; James F Chmiel; Michael W Konstan
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

Review 10.  Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onset.

Authors:  Geraint B Rogers; Lucas R Hoffman; Matt W Johnson; Nicole Mayer-Hamblett; Jürgen Schwarze; Mary P Carroll; Kenneth D Bruce
Journal:  Expert Rev Mol Diagn       Date:  2011-03       Impact factor: 5.225

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.